<DOC>
	<DOCNO>NCT00372073</DOCNO>
	<brief_summary>This randomized Phase II study experimental anti-cancer drug call seliciclib . The main objective study learn , long , seliciclib keep non-small cell lung cancer check . An experimental drug drug approve U.S. Food Drug Administration ( FDA ) regulatory agency marketing still study determine safe , side-effects , whether effective treatment non-small cell lung cancer .</brief_summary>
	<brief_title>Efficacy Study Oral Seliciclib Treat Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Roscovitine</mesh_term>
	<criteria>Adult patient histologicallyconfirmed recurrent nonsmall cell lung cancer least two prior systemic treatment regimen Must measurable disease accord RECIST Eastern Cooperative Oncology Group performance status 01 Adequate bone marrow , hepatic renal function Ability swallow capsule At least 3 week prior systemic treatment include investigational anticancer therapy , least 7 day prior radiation therapy recover prior toxicity At least 3 week major surgery Nonsmall cell cancer histology contain component small cell lung cancer Previously untreated CNS metastasis progressive CNS metastasis Prior treatment CDK inhibitor Currently receive radiotherapy , biological therapy , investigational therapy Uncontrolled intercurrent illness Having cancer treat chemotherapy biological therapy past 5 year exception adequately treat situ cervical cancer basal cell skin cancer Pregnant lactate woman Known HIVpositive Active hepatitis B and/or hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>